SMSimona Malaspina

Simona Malaspina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Simona Malaspina has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of [18F]DCFPyL and [18F]FAPI-74 PET/CT imaging in metastatic prostate cancer

    by Anniina Hyväkkä, Marko Seppänen, Maria Sundvall, Veera Sivonen, Kalle Mattila, Mikael Anttinen, Otto Ettala, Mikael Högerman, Anna Kirjavainen, Olli Eskola, et al.

    Purpose: To compare prostate-specific membrane antigen (PSMA) and fibroblast activation-protein inhibitor (FAPI) targeted PET/CT imaging to assess possible theranostic combination strategies of both tracers in metastatic prostate cancer (mPC). Methods: This prospective study enrolled patients with mPC who underwent long-axial field-of-view whole-body PET/CT with 18 F-DCFPyL and 18 F-FAPI-74 within two weeks. Fifteen patients had hormone sensitive (mHSPC) and 24 castration-resistant (mCRPC) disease. Scans were reviewed according to predefined criteria, with up to five metastases per anatomical region evaluated. Lesions were categorized in four groups as skeletal, pelvic nodal, extrapelvic nodal, or visceral. SUVmax and volumetric parameters were measured for each lesion and at the patient level. Results: A total of 1365 lesions were identified in 39 patients. 18 F-DCFPyL PET/CT detected 1351 lesions (99%). In contrast, 18 F–FAPI-74 identified only 788 (58%) lesions in the PSMA-guided analysis and 523 (38%) lesions in the independent analysis. Median lesion SUVmax was higher for PSMA (24) than for FAPI (5.4) (p < 0.001). Visceral metastases constituted 3% of lesions with both tracers and tended to be more often FAPI-avid (64%) compared to other lesion groups. Only 14 (1%) of lesions were FAPI-positive and PSMA-negative. In whole-tumor burden analysis, median tracer-positive tumor volume on 18 F-DCFPyL PET/CT was 85 mL and on 18 F-FAPI-74 PET/CT only 10 mL (p < 0.001). Conclusion: In mPC, PSMA PET/CT remains the preferred molecular imaging method. Our findings suggest only a limited role of FAPI radioligand therapy. FAPI theranostics should focus on patients with visceral metastases and specific histological subtypes beyond acinar adenocarcinoma. Clinical Trial Registration: EudraCT: 2022–003788-13. Registered 21 September 2023


  • Open Access

    Deep learning‐based 3D classification of head and neck cancer PET/MRI: Radiologist comparison and Grad‐CAM interpretability

    by Joonas Liedes, Jussi Hirvonen, Oona Rainio, Sarita Murtojärvi, Simona Malaspina, Riku Klén, Jukka Kemppainen

    Purpose: To develop and evaluate a three‐dimensional convolutional neural network for automated classification of PET/MRI images in head and neck cancer (HNC) patients, assessing its performance against radiologist interpretation and its potential as a diagnostic aid.Methods: Data from 202 patients with HNC who underwent 18F‐FDG PET/MRI were used to train and validate PET‐, MRI‐, and PET/MRI‐based models. Of these data, 101 patients were labelled as positive in terms of having HNC, and 101 patients as negative. An additional test set of 20 patients was also evaluated, where 10 patients were labelled as positive and 10 as negative. The model performance was assessed using sensitivity, specificity, accuracy, and AUC. Grad‐CAM was utilised to improve interpretability and classification results on the test set were compared with a radiologist.Results: The PET‐based model achieved an AUC of 0.92 on the test set, with an accuracy of 90%, a sensitivity of 100% and a specificity of 80%. PET/MRI and MRI‐based models underperformed relative to the PET‐based model. The radiologist achieved perfect classification accuracy. Analysis of Grad‐CAM showed that the model classifications are based on real areas of interest. In addition, it gave valuable insight into using similar systems in identifying false positive findings.Conclusion: The PET‐based model demonstrated high sensitivity, indicating its potential as a pre‐screening tool for HNC. However, specificity requires improvement to reduce false‐positive rates. Enhanced datasets and refinement of model architecture will be crucial before clinical adoption. Grad‐CAM provides valuable insights into model decisions, aiding clinical integration.


  • Open Access

    Prospective comparison of 18F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer

    by Aino Kivikallio, Simona Malaspina, Irena Saarinen, Marko Seppänen, Mikael Anttinen, Ivan Jambor, Janne Verho, Jukka Kemppainen, Hannu J. Aronen, Peter J. Boström, et al.

    Purpose: To prospectively compare the ability of 18F-PSMA-1007 PET/CT and whole-body MRI (WBMRI) with DWI to detect prostate cancer (PCa) lesions and assess their local stage. Additionally, to evaluate the correlation between PSMA uptake on PET/CT and PSMA expression as assessed by immunohistochemistry. Methods: Men with newly diagnosed unfavourable intermediate or high-risk PCa underwent 18F-PSMA-1007 PET/CT and WBMRI with DWI before robot-assisted laparoscopic prostatectomy. Diagnostic accuracy for intraprostatic tumour localization, seminal vesicle invasion (SVI), and extraprostatic extension (EPE) was evaluated using whole-mount prostatectomy specimens as the reference standard. SUVmax was compared with immunohistochemical PSMA staining intensity quantified using QuPath software. Results: 19 patients with 39 intraprostatic lesions in histopathology were included. The overall lesion detection rates for PET/CT were 84.6% and 82.1% for two independent readers, compared to 74.4% and 46.2% for MRI readers. The detection rates of index lesions were 94.7% for PET/CT and 74.0–84.0% for MRI, whereas those of non-index lesions were 70.0–75.0% for PET/CT and 20.0–65.0% for MRI. For detecting EPE, AUC values were 0.500-0.591 for PET/CT and 0.648–0.682 for MRI. For detecting SVI, AUC values ranged from 0.629 to 0.700 across both modalities. SUVmax showed a weak correlation with immunohistochemical expression of PSMA multiplied by lesion diameter (Spearman’s ρ = 0.427, p = 0.013). Lesion diameters measured using 30% and 40% of SUVmax, as well as prostate SUVbackground x2, showed the closest agreement with histopathological measurements. Conclusion: 18F-PSMA-1007 PET/CT demonstrated high sensitivity in localizing intraprostatic carcinoma lesions but seemed inferior to WBMRI in detecting EPE. PSMA uptake appears to depend on both PSMA expression and lesion size. These findings highlight the complementary roles of PET/CT and MRI in the detection and tumor staging of PCa. Clinical trial registration: Clinicaltrials.gov ID: NCT03537391. Registered 25 May 2018.


  • Open Access

    One-click annotation to improve segmentation by a convolutional neural network for PET images of head and neck cancer patients

    by Oona Rainio, Joonas Liedes, Sarita Murtojärvi, Simona Malaspina, Jukka Kemppainen, Riku Klén

    A convolutional neural network (CNN) can be used to perform fully automatic tumor segmentation from the positron emission tomography (PET) images of head and neck cancer patients but the predictions often contain false positive segmentation caused by the high concentration of the tracer substance in the human brain. A potential solution would be a one-click annotation in which a user points the location of the tumor by clicking the image. This information can then be given either directly to a CNN or an algorithm that fixes its predictions. In this article, we compare the fully automatic segmentation to four semi-automatic approaches by using 962 transaxial slices collected from the PET images of 100 head and neck cancer patients. According to our results, a semi-automatic segmentation method with information about the center of the tumor performs the best with a median Dice score of 0.708.


  • Open Access

    Automatic Segmentation of Head and Neck Cancer from PET-MRI Data Using Deep Learning

    by Joonas Liedes, Henri Hellström, Oona Rainio, Sarita Murtojärvi, Simona Malaspina, Jussi Hirvonen, Riku Klén, Jukka Kemppainen

    Purpose: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancer types globally. Due to the complex anatomy of the region, diagnosis and treatment is challenging. Early diagnosis and treatment are important, because advanced and recurrent HNSCC have a poor prognosis. Robust and precise tools are needed to help diagnose HNSCC reliably in its early stages. The aim of this study was to assess the applicability of a convolutional neural network in detecting and auto-delineating HNSCC from PET-MRI data. Methods: 2D U-net models were trained and tested on PET, MRI, PET-MRI and augmented PET-MRI data from 44 patients diagnosed with HNSCC. The scans were taken 12 weeks after chemoradiation therapy with a curative intention. A proportion of the patients had follow-up scans which were included in this study as well, giving a total of 62 PET-MRI scans. The scans yielded a total of 178 PET-MRI slices with cancer. A corresponding number of negative slices were chosen randomly yielding a total of 356 slices. The data was divided into training, validation and test sets (n = 247, n = 43 and n = 66 respectively). Dice score was used to evaluate the segmentation accuracy. In addition, the classification capabilities of the models were assessed. Results: When true positive segmentations were considered, the mean Dice scores for the test set were 0.79, 0.84 and 0.87 for PET, PET-MRI and augmented PET-MRI, respectively. Classification accuracies were 0.62, 0.71 and 0.65 for PET, PET-MRI and augmented PET-MRI, respectively. The MRI based model did not yield segmentation results. A statistically significant difference was found between the PET-MRI and PET models (p = 0.008). Conclusion: Automatic segmentation of HNSCC from the PET-MRI data with 2D U-nets was shown to give sufficiently accurate segmentations.


  • Open Access

    Classification of head and neck cancer from PET images using convolutional neural networks

    by Henri Hellström, Joonas Liedes, Oona Rainio, Simona Malaspina, Jukka Kemppainen, Riku Klén

    The aim of this study was to develop a convolutional neural network (CNN) for classifying positron emission tomography (PET) images of patients with and without head and neck squamous cell carcinoma (HNSCC) and other types of head and neck cancer. A PET/magnetic resonance imaging scan with 18F-fluorodeoxyglucose (18F-FDG) was performed for 200 head and neck cancer patients, 182 of which were diagnosed with HNSCC, and the location of cancer tumors was marked to the images with a binary mask by a medical doctor. The models were trained and tested with five-fold cross-validation with the primary data set of 1990 2D images obtained by dividing the original 3D images of 178 HNSCC patients into transaxial slices and with an additional test set with 238 images from the patients with head and neck cancer other than HNSCC. A shallow and a deep CNN were built by using the U-Net architecture for classifying the data into two groups based on whether an image contains cancer or not. The impact of data augmentation on the performance of the two CNNs was also considered. According to our results, the best model for this task in terms of area under receiver operator characteristic curve (AUC) is a deep augmented model with a median AUC of 85.1%. The four models had highest sensitivity for HNSCC tumors on the root of the tongue (median sensitivities of 83.3–97.7%), in fossa piriformis (80.2–93.3%), and in the oral cavity (70.4–81.7%). Despite the fact that the models were trained with only HNSCC data, they had also very good sensitivity for detecting follicular and papillary carcinoma of thyroid gland and mucoepidermoid carcinoma of the parotid gland (91.7–100%).


  • Open Access

    Single Center Experience with a 4-Week 177Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer

    by Jukka Kemppainen, Aki Kangasmäki, Simona Malaspina, Bernd Pape, Jarno Jalomäki, Kalevi Kairemo, Juha Kononen, Timo Joensuu

    Background: 177Lu-PSMA-617 is a promising theragnostic treatment for metastatic castration-resistant prostate cancer (mCRPC). However, both the optimal treatment dose and interval in mCRPC and the rate of identification of responders from non-responders among possible treatment candidates are unknown. Methods: 62 men with mCRPC who were treated with 177Lu-PSMA-617 during 1/2017–2/2019 were included in the study. Treatment responses, overall survival (OS) and progression free survival (PFS) were determined. The median follow-up time was 1.4 years (IQR 0.5–2.2). Tumor volume of metastases (MTV), SUVmax and tumor lesion activity (TLA) were quantitated from pre-treatment PSMA PET/CT images together with pre-treatment PSA. Results: An average of three treatment cycles (2–5) were given within a four-week interval. PFS was 4.9 months (2.4–9.6) and OS was 17.2 months (6–26.4). There were no major adverse events reported. A significant PSA response of >50% was found in 58.7% of patients, which was significantly associated with longer OS, p < 0.004. PSA response was not associated with staging PSMA-derived parameters. Conclusions: 177Lu-PSMA-617 treatment in four-week intervals was safe and effective. Almost 60% of patients had a significant PSA response, which was associated with better OS. Pre-treatment PSA kinetics or staging PSMA PET/CT-derived parameters were not helpful in identifying treatment responders from non-responders; better biomarkers are needed to aid in patient selection.


  • Open Access

    Flare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients

    by Simona Malaspina, Otto Ettala, Tuula Tolvanen, Johan Rajander, Olli Eskola, Peter. J. Boström, Jukka Kemppainen

    Purpose: Short-term androgen deprivation therapy (ADT) is known to increase heterogeneously prostate-specific membrane antigen (PSMA) expression. This phenomenon might indicate the potential of cancer lesions to respond to ADT. In this prospective study, we evaluated the flare on [18F]PSMA-1007 PET/CT after ADT in metastatic prostate cancer (PCa). Given that aggressive PCa tends to display FDG uptake, we particularly investigated whether the changes in PSMA uptake might correlate with glucose metabolism. Methods: Twenty-five men with newly diagnosed treatment-naïve metastatic PCa were enrolled in this prospective registered clinical trial. All the patients underwent [18F]PSMA-1007 PET/CT immediately before and 3–4 weeks after ADT initiation (degarelix). Before ADT, [18F]FDG PET/CT was also performed. Standardized uptake values (SUV)max of primary and metastatic lesions were calculated in all PET scans. Serum PSA and testosterone blood samples were collected before the two PSMA PET scans. The changes in PSMA uptake after ADT were represented as ΔSUVmax. Results: All the patients reached castration levels of testosterone at the time of the second [18F]PSMA-1007 PET/CT. Overall, 57 prostate, 314 lymph nodes (LN), and 406 bone lesions were analyzed. After ADT, 104 (26%) bone, 33 (11%) LN, and 6 (11%) prostate lesions showed an increase (≥ 20%) in PSMA uptake, with a median ΔSUVmax of + 50%, + 60%, and + 45%, respectively. Among the lesions detected at the baseline [18F]PSMA-1007 PET/CT, 63% bone and 46% LN were FDG-positive. In these metastases, a negative correlation was observed between the PSMA ΔSUVmax and FDG SUVmax (p < 0.0001). Moreover, a negative correlation between the ΔSUVmax and the decrease in serum PSA after ADT was noted (p < 0.0001). Conclusions: A heterogeneous increase in PSMA uptake after ADT was detected, most evidently in bone metastases. We observed a negative correlation between the PSMA flare and the intensity of glucose uptake as well as the decrease of serum PSA, suggesting that lesions presenting with such flare might potentially be less aggressive. Trial registration: NCT03876912, registered 15 March 2019.


  • Open Access

    Diagnostic Accuracy of 18F‐FDG‐PET/CT and 18F‐FDG‐PET/MRI in Detecting Locoregional Recurrence of HNSCC 12 Weeks after the End of Chemoradiotherapy: Single‐Center Experience with PET/MRI

    by Sarita Murtojärvi, Simona Malaspina, Ilpo Kinnunen, Terhi Tuokkola, Miikka-Juhani Honka, Virva Saunavaara, Tuula Tolvanen, Aleksi Schrey, Jukka Kemppainen

    Purpose. In head and neck squamous cell carcinoma (HNSCC), the early diagnosis and efficient detection of recurrences and/or residual tumor after treatment play a very important role in patient’s prognosis. Positron emission tomography (PET) using 2‐deoxy‐2‐18F‐fluoro‐D‐glucose (18F‐FDG) has become an established method for the diagnosis of suspected recurrence in head and neck carcinomas. In particular, integrated PET/MRI imaging that provides optimal soft tissue contrast and less dental implant artifacts compared to PET/CT is an intriguing technique for the follow‐up imaging of HNSCC patients. The aim of this study was to evaluate the benefit of PET/MRI compared to PET/CT in post‐treatment follow‐up imaging of HNSCC patients. Methods. This retrospective observational cohort study consists of 104 patients from our center with histologically confirmed HNSCC. All patients received chemoradiotherapy (CRT) and underwent 18F‐FDG‐PET/CT (n = 52) or 18F‐FDG‐PET/MRI (n = 52) scan 12 weeks after the end of treatment. Image analysis was performed by two independent readers according to a five‐point Likert scale analysis. Results. PET/MRI was more sensitive (1.00 vs. 0.77) than PET/CT in the detection of locoregional recurrence. PET/MRI also had better negative (1.00 vs. 0.87) predictive values. AUCs for PET/MRI and PET/CT on patient‐based analysis were 0.997 (95% CI 0.989–1.000) and 0.890 (95% CI 0.806–0.974), respectively. The comparison of sensitivity, AUCs, and negative predictive values revealed a statistically significant difference, p < 0.05. In PET/CT, false‐negative and positive findings were observed in the more advanced disease stages, where PET/MRI performed better. Also, false‐negative findings were located in the oropharyngeal, laryngeal, and nasopharyngeal regions, where PET/MRI made no false‐negative interpretations. Conclusion. Based on these results, PET/MRI might be considered the modality of choice in detecting locoregional recurrence in HNSCC patients, especially in the more advanced stages in the oral cavity, larynx, or nasopharynx.


  • Open Access

    Hepatic Positron Emission Tomography: Applications in Metabolism, Haemodynamics and Cancer

    by Miikka-Juhani Honka, Eleni Rebelos, Simona Malaspina, Pirjo Nuutila

    Evaluating in vivo the metabolic rates of the human liver has been a challenge due to its unique perfusion system. Positron emission tomography (PET) represents the current gold standard for assessing non-invasively tissue metabolic rates in vivo. Here, we review the existing literature on the assessment of hepatic metabolism, haemodynamics and cancer with PET. The tracer mainly used in metabolic studies has been [18F]2-fluoro-2-deoxy-D-glucose (18F-FDG). Its application not only enables the evaluation of hepatic glucose uptake in a variety of metabolic conditions and interventions, but based on the kinetics of 18F-FDG, endogenous glucose production can also be assessed. 14(R,S)-[18F]fluoro-6-thia-Heptadecanoic acid (18F-FTHA), 11C-Palmitate and 11C-Acetate have also been applied for the assessment of hepatic fatty acid uptake rates (18F-FTHA and 11C-Palmitate) and blood flow and oxidation (11C-Acetate). Oxygen-15 labelled water (15O-H2O) has been used for the quantification of hepatic perfusion. 18F-FDG is also the most common tracer used for hepatic cancer diagnostics, whereas 11C-Acetate has also shown some promising applications in imaging liver malignancies. The modelling approaches used to analyse PET data and also the challenges in utilizing PET in the assessment of hepatic metabolism are presented.